Innovation Pharmaceuticals Inc (IPIX)

[F1ash]

Seems perhaps the decision makers at Cellceutix have a pretty good idea what they are doing.




"The Psoriasis Area and Severity Index is the most commonly used clinical measure in research, but it has substantial limitations such as low response distribution, no consensus on interpretability, and low responsiveness in mild disease. "

"The main conclusion is that there are no adequately vali- dated clinical measures for psoriasis. As there is no supreme measure, different measures might be ideal for different situations and we might need all of them. When choosing a measure, it is important to determine the most needed features, for example, good responsiveness or sensitivity in mild disease. It may be necessary to combine two or more scores to satisfy all needs. For example, PASI may not be particularly sensitive for mild disease, ..."





http://ac.els-cdn.com/S0022202X15347643/1-s2.0-S0022202X15347643-main.pdf?_tid=cba3dccc-f2fd-11e5-8cfa-00000aab0f01&acdnat=1458960936_0b2a1b1206d027e8b281f6a79c2e2aae